title: Serum concentrations of insulin-like growth factors (IGFs), IGF binding proteins 1 and 3 and growth hormone binding protein in obese women and the effects of growth hormone administration: a double-blind, placebo-controlled study.
abstract: Obesity is associated with suppressed growth hormone (GH) concentrations but relatively little is known about insulin-like growth factors(IGFs) and binding proteins for GH and IGFs (GHBP and IGFBPs) and the modulatory effect of GH administration. In a double-blind, crossover design we studied the impact of 5 weeks of placebo or GH administration (0.03 mg.kg-1 body wt.day-1) in nine obese women (mean +/- SEM: age 30.4 +/- 2.4 years; body mass index 37.0 +/- 2.8 kg/m2) on IGF-I, IGF-II, IGFBP-1 and -3 and GHBP. Serum IGF-I (microgram/l) levels were subnormal and increased significantly following GH (117 +/- 16 (placebo) vs 434 +/- 33 (GH) vs 198 +/- 15 (control (p < 0.01)). By contrast, serum IGF-II (microgram/l) levels were in the normal range and remained unchanged (608 +/- 20 (placebo) vs 647 +/- 40 (GH) (NS)). Serum IGFBP-3 was in the normal range and increased significantly during GH treatment, although relatively less than IGF-I, such that the molar ratio between IGF-I and IGFBP-3 increased with GH treatment, whereas the ratio between IGF-I + IGF-II and IGFBP-3 remained unchanged. Serum IGFBP-1 was low in the placebo situation but became further and almost completely suppressed during GH treatment. During a 2-h hyperinsulinemic, euglycemic glucose clamp, IGFBP-1 decreased in the placebo study and remained suppressed during GH. Serum GHBP (nmol/l) levels were elevated substantially compared to non-obese controls (p < 0.001) and did not change during GH treatment (2.37 +/- 0.36 (placebo) vs 2.21 +/- 0.25 (GH) vs 0.80 +/- 0.19 (control)).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Medical Department M (Endocrinology and Diabetes), Aarhus Kommunehospital, Denmark.
authors.forename: J O
authors.initials: JO
authors.lastname: Jørgensen
authors.forename: S B
authors.initials: SB
authors.lastname: Pedersen
authors.forename: J
authors.initials: J
authors.lastname: Børglum
authors.forename: J
authors.initials: J
authors.lastname: Frystyk
authors.forename: K K
authors.initials: KK
authors.lastname: Ho
authors.forename: J S
authors.initials: JS
authors.lastname: Christiansen
authors.forename: H
authors.initials: H
authors.lastname: Orskov
authors.forename: W F
authors.initials: WF
authors.lastname: Blum
authors.forename: B
authors.initials: B
authors.lastname: Richelsen
mesh_terms: D000328:Adult; D015992:Body Mass Index; D002352:Carrier Proteins / Q000097:blood*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D013006:Growth Hormone / Q000008:administration & dosage*; D006801:Humans; D018970:Insulin-Like Growth Factor Binding Protein 1; D018969:Insulin-Like Growth Factor Binding Proteins; D009765:Obesity / Q000097:blood*; D013002:Somatomedins / Q000032:analysis*
chemical_list: D002352:Carrier Proteins; D018970:Insulin-Like Growth Factor Binding Protein 1; D018969:Insulin-Like Growth Factor Binding Proteins; D013002:Somatomedins; D013006:Growth Hormone; C051815:somatotropin-binding protein